Bazedoxifeneのソースを表示

{{Short description|Selective estrogen receptor modulator}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 413883166
| IUPAC_name = 1-[4-[2-(azepan-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1''H''-indol-5-ol
| image = Bazedoxifene.svg
| width = 225px
| image2 = Bazedoxifene-3D-balls.png
| width2 = 225px

<!--Clinical data-->
| tradename = Conbriza, Duavee, Duavive, Viviant
| Drugs.com = {{drugs.com|international|bazedoxifene}}
| licence_EU = yes
| pregnancy_category =
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|By mouth]]

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 7355
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 198481-32-2
| ATC_prefix = G03
| ATC_suffix = XC02
| PubChem = 154257
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06401
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 135921
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = Q16TT9C5BK
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 46740
| PDB_ligand = 29S
| synonyms = TSE-424; WAY-140424; WAY-TSE-424

<!--Chemical data-->
| C=30 | H=34 | N=2 | O=3
| SMILES = Oc1ccc(cc1)c3c(c2cc(O)ccc2n3Cc5ccc(OCCN4CCCCCC4)cc5)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UCJGJABZCDBEDK-UHFFFAOYSA-N
}}

'''Bazedoxifene''', used as '''bazedoxifene acetate''', is a [[pharmaceutical drug|medication]] for [[bone]] problems and possibly (pending more study) for cancer.<ref name="Duavee-Label">{{Cite web |date=October 2013 |title=DUAVEE® (conjugated estrogens/bazedoxifene) tablets for oral use |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022247Orig1s001lbl.pdf |publisher=U.S. Food and Drug Administration}}</ref> It is a third-generation [[selective estrogen receptor modulator]] (SERM).<ref name="pmid18044180">{{Cite journal |vauthors=Biskobing DM |year=2007 |title=Update on bazedoxifene: a novel selective estrogen receptor modulator |journal=Clinical Interventions in Aging |volume=2 |issue=3 |pages=299–303 |pmc=2685267 |pmid=18044180}}</ref> Since late 2013 it has had U.S. [[Food and Drug Administration|FDA]] approval for bazedoxifene as part of the [[combination drug]] [[Duavee]] in the prevention (not treatment) of [[menopause|postmenopausal]] [[osteoporosis]]. It is also being studied for possible treatment of [[breast cancer]] and [[pancreatic cancer]].<ref>{{Cite web |date=June 15, 2013 |title=Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors |url=http://medicalxpress.com/news/2013-06-osteoporosis-drug-growth-breast-cancer.html |publisher=Duke University Medical Center}}</ref>